Lysosomal compartment and autophagy machinery (ALP)

The lysosomal compartment and autophagy machinery constitute the primary degradative system of the eukaryotic cell, essential for maintaining proteostasis and organelle quality control (Mizushima & Komatsu, 2011). Autophagy is a multi-step process where cytoplasmic materials are sequestered into double-membraned vesicles called autophagosomes, which then fuse with lysosomes to undergo degradation by acidic hydrolases (Klionsky et al., 2021). This machinery serves as a critical metabolic sensor, regulated primarily by the mTOR and AMPK pathways to balance nutrient availability with cellular demand (Settembre et al., 2013). In disease contexts, dysfunction of this system is linked to the accumulation of toxic protein aggregates in neurodegeneration and the development of lysosomal storage disorders. Conversely, in oncology, the pathway is often upregulated to help cancer cells survive hypoxia and nutrient deprivation, making it a target for therapeutic inhibition (Amaravadi et al., 2019). Therapeutic strategies include the use of lysosomotropic agents to block degradation or mTOR inhibitors to enhance clearance of pathogenic substrates. Because these processes are fundamental to all eukaryotic cells, achieving tissue-specific modulation without significant off-target toxicity remains a primary therapeutic challenge.

Other names

Autophagy-lysosome pathwayLysosomal-autophagic systemMacroautophagy machineryCellular degradative machinery

Drugs targeting this machinery typically act by either inhibiting lysosomal acidification and autophagosome-lysosome fusion (e.g., chloroquine) or by inducing autophagy through the inhibition of the mechanistic target of rapamycin (mTOR) complex 1, which normally suppresses the initiation of the autophagic process.